{"schema_version":"secwatch.filing_event.v1","accession":"0001411690-24-000020","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.308332+00:00","generated_at":"2026-06-02T09:30:23.448844+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bionano Q1 revenue $8.8M (+18% YoY); cash burn down 41% YoY; restructuring charges $4.6M","bullets":["Q1 2024 revenue $8.8M, +18% YoY; GAAP gross margin 32% vs 28% in Q1 2023.","Operating cash burn (excl. interest/debt) $19M in Q1 2024, down from $32M in Q1 2023.","Reaffirmed FY2024 revenue guidance of $37-41M; Q2 2024 revenue expected $7.8-8.2M.","Installed base of 347 OGM systems (+34% YoY); flowcell sales up 58% to 8,249 units.","Restructuring charges of ~$4.6M from March 2024 RIF; substantially complete by June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001411690-24-000020","json":"https://secwatch.observer/filing/0001411690-24-000020.json","markdown":"https://secwatch.observer/filing/0001411690-24-000020.md","text":"https://secwatch.observer/filing/0001411690-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/bngo-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:30:23.448844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef1dac3b803c6a08d8acbb63f1535408a02590ff","claim":"Bionano Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $8.8 million. Guidance reaffirmed.","evidence_excerpt":"filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress • Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 • Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$8.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a37355c11fd2c20a56a4f594f54bca32edbfead8","claim":"Bionano Genomics, Inc. announced a restructuring with charges of approximately $4.6 million.","evidence_excerpt":"the Reduction is expected to result in total restructuring charges of approximately $4.6 million, including $3.9 million, comprised primarily of severance payments and wages for the 60-day notice period in accordance with the California Worker Adjustment and Retraining Notification (WARN) Act and $0.2 million in connection with lease terminations.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.6 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}